Glenmark passes the benefits to patients by reducing the price of oral antiviral FabiFlu by 27 in India

  • | Thursday | 16th July, 2020

Further, Glenmark has announced a price reduction of27% for FabiFlu®. FabiFlu® in India was originally launched at INR 103/tab, while, its price as INR is higher in the remaining countries. (INR 600/tab in Russia, INR 378/tab in Japan, INR 350/tab in Bangladesh and INR 215/tab in China). Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu®) in mild to moderate COVID-19 patients in India. The combination study which is called the FAITH trial is looking to enroll 158 hospitalized patients of moderate COVID-19 in India.

Read Full Article Here

Stay updated with all the Latest Cuttack headlines here. For more exclusive & live news updates from all around India, stay connected with NYOOOZ.

Related Articles